Antimicrobial Peptides for Plaque Control

Baker PJ, Coburn RA, Genco RJ, Evans RT (1978). The in vitro inhibition of microbial growth and plaque formation by surfactant drugs. J Periodontal Res 13:474–485.

Bierbaum G, Sahl HG (1985). Induction of autolysis of staphylococci by the basic peptide antibiotics Pep 5 and nisin and their influence on the activity of autolytic enzymes. Arch Microbiol 141:249–254.

Chen P, Cisar JO, Hess S, Ho JT, Leung KP (2007). Amended description of the genes for synthesis of Actinomyces naeslundii T14V type 1 fimbriae and associated adhesin. Infect Immun 75:4181–4185.

Concannon SP, Crowe TD, Abercrombie JJ, Molina CM, Hou P, Sukumaran DK, et al. (2003). Susceptibility of oral bacteria to an antimicrobial decapeptide. J Med Microbiol 52:1083–1093.

Faraj JA, Dorati R, Schoubben A, Worthen D, Selmin F, Capan Y, et al. (2007). Development of a peptide-containing chewing gum as a sustained release antiplaque antimicrobial delivery system. AAPS PharmSciTech 8(1): 26.

Fernandez-Lopez S, Kim HS, Choi EC, Delgado M, Granja JR, Khasanov A, et al. (2001). Antibacterial agents based on the cyclic D, L-alpha-peptide architecture. Nature 412:452–455.

Finlay BB, Hancock RE (2004). Can innate immunity be enhanced to treat microbial infections? Nat Rev Microbiol 2:497–504.

Hall MJ, Middleton RF, Westmacott D (1983). The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother 11:427–433.

Koczulla AR, Bals R (2003). Antimicrobial peptides: current status and therapeutic potential. Drugs 63:389–406.

Kolenbrander PE, Palmer RJ Jr (2004). Human oral bacterial biofilms. In: Microbial biofilms. Ghannoum M, O’Toole GA, editors. Washington, DC: ASM press, pp. 85–117.

Leung KP, Crowe TD, Abercrombie JJ, Molina CM, Bradshaw CJ, Jensen CL, et al. (2005). Control of oral biofilm formation by an antimicrobial decapeptide. J Dent Res 84:1172–1177.

Löe H, Theilade E, Jensen SB (1965). Experimental gingivitis in man. J Periodontol 36:177–187.

Loesche WJ (1999). The antimicrobial treatment of periodontal disease: changing the treatment paradigm. Crit Rev Oral Biol Med 10:245–275.

Marsh PD (2005). Dental plaque: biological significance of a biofilm and community life-style. J Clin Periodontol 32(Suppl 6):7–15.

Marsh PD (2006). Dental plaque as a biofilm and a microbial community—implications for health and disease. BMC Oral Health 6(Suppl 1):14.

Matsuzaki K (1999). Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim Biophys Acta 1462:1–10.

Na DH, Faraj J, Capan Y, Leung KP, DeLuca PP (2007). Stability of antimicrobial decapeptide (KSL) and its analogues for delivery in the oral cavity. Pharm Res 24:1544–1550.

Park CB, Kim HS, Kim SC (1998). Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun 244:253–257.

Pini A, Giuliani A, Falciani C, Fabbrini M, Pileri S, Lelli B, et al. (2007). Characterization of the branched antimicrobial peptide M6 by analyzing its mechanism of action and in vivo toxicity. J Pept Sci 13:393–399.

Raj PA, Dentino AR (2002). Current status of defensins and their role in innate and adaptive immunity. FEMS Microbiol Lett 206:9–18.

Rölla G, Waaler SM, Kjaerheim V (1998). Concepts in dental plaque formation. In: Oral biofilms and plaque control. Busscher HJ, Buckingham LV, editors. UK: Routledge, Taylor & Francis Group, pp. 1–17.

Rudney JD (2000). Saliva and dental plaque. Adv Dent Res 14:29–39.

Shellis RP (1978). A synthetic saliva for cultural studies of dental plaque. Arch Oral Biol 23:485–489.

Silverman JA, Perlmutter NG, Shapiro HM (2003). Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 47:2538–2544.

Singh PK, Tack BF, McCray PB Jr, Welsh MJ (2000). Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physiol 279:L799–L805.

Westerhoff HV, Juretic D, Hendler RW, Zasloff M (1989). Magainins and the disruption of membrane-linked free-energy transduction. Proc Natl Acad Sci USA 86:6597–6601.

Williams MI (1998). Pre-clinical evaluation of plaque control agents: value of in vitro models. In: Oral biofilms and plaque controls. Busscher HJ, Buckingham LV, editors. UK: Routledge, Taylor & Francis Group, pp. 261–276.

Wu M, Maier E, Benz R, Hancock RE (1999). Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli. Biochemistry 38:7235–7242.

Yang L, Weiss TM, Lehrer RI, Huang HW (2000). Crystallization of antimicrobial pores in membranes: magainin and protegrin. Biophys J 79:2002–2009; erratum in Biophys J 80:1029, 2001.

Zasloff M (2002). Antimicrobial peptides of multicellular organisms. Nature 415:389–395.